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Pyoderma gangrenosum (PG) is an idiopathic,
ulcerating neutrophilic dermatosis.1 We present a
patient with 12 years of peristomal PG recalcitrant to
numerous steroids and immunosuppressants who
attained complete remission after iron sucrose
infusion.
CASE REPORT
A 30-year-old woman with a history of Crohn’s
disease presented to the clinic shortly after
placement of a diverting ileostomy with peristomal
purulence, ulceration, and erythema (Fig 1).
Biopsy-proven PG was diagnosed, and she was
started on prednisone and intralesional triamcino-
lone. Over the next 10 years, she was prescribed
various combinations of cyclosporine, intralesional
triamcinolone, mycophenolate mofetil, dapsone,
topical cyclosporine, colchicine, etanercept, and
prednisone for repeated peristomal PG flares.
These medications prevented severe painful flares
but failed to cure the chronic peristomal ulcerations.
During this time of multiple medication trials, her
Crohn’s disease was in remission, requiring no
additional Crohn’s-specific medication. Throughout
the course of her treatment, the patient experienced
significant fatigue, and her hemoglobin level
oscillated between 9.2 and 11.7 g/dL (normal,
12.3-15.7 g/dL) with ferritin levels less than
50 ng/mL (normal, 10-250 ng/mL). Iron studies
suggested a combination of anemia of chronic
disease and iron deficiency anemia; thus, she
received six parenteral iron sucrose infusions over
the course of 6 months. After the first 3 infusions, her
ferritin level increased from 47 to 198 ng/mL. Her
fatigue improved temporarily but shortly returned to
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Case Reports 2015;1:54-5.iron therapy in late February of 2013, and her ferritin
levels reached 547 ng/mL. In mid-March the patient
noted visible improvement in the PG and lasting
resolution of her fatigue and malaise. By late June,
her peristomal PG had healed completely, and
she was able to wean off of mycophenolate and
cyclosporine. She continues to remain in remission
from PG and Crohn’s today, more than 1 year after
resolution of her PG (Fig 2).
DISCUSSION
Anemia is common in patients with PG, with an
overall prevalence reported at 65.2% and microcytic
anemia reported at 15.5%,2 yet, there are no
substantial data investigating the effects of anemia
treatment directly on chronic inflammatory
disorders. We propose that there may be an
inhibitory effect of the iron sucrose itself on the
functioning of hyperactive neutrophils and their role
in the pathogenicity of PG.
In hemodialysis patients, parenteral iron sucrose
infusions have been shown to induce oxidative stress
and impair phagocytic activity and oxidative burst
capacity of neutrophils.3,4 Neutrophilic function was
slightly altered in those with ferritin levels between
100 and 350 ng/mL and significantly altered in
patients with ferritin levels greater than 650 ng/mL.
Furthermore, Sengoelge et al5 found that iron
sucrose significantly inhibited transendothelial
migration of neutrophils in vitro. In addition, there
may be a downregulatory effect of high ferritin levels
on various cytokines that promote inflammation and2352-5126
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Fig 1. Peristomal purulence, ulceration, and erythema
persisted nearly 10 years despite conventional therapy.
Fig 2. After 6 parenteral iron sucrose infusions, the
patient’s wounds healed, leaving a healthy peristomal
area. She remains in remission today, medication free.
JAAD CASE REPORTS
VOLUME 1, NUMBER 2
Buhalog, Eastman, and McDonald 55delay wound healing. Studies of PG show
elevated levels of matrix metalloproteinase-9,
metalloproteinase-10, and tumor necrosis factor-
alfa.6 Overexpression of ferritin has shown
to decrease levels of tumor necrosis factor in
inflammatory processes,7 although no data yet existregarding parenteral iron’s influence on matrix
metalloproteinases.
High ferritin levels, as would result from iron
sucrose infusions, inhibit neutrophil function, migra-
tion, and various inflammatory cytokines. Thus, it is
possible that our patient entered remission after iron
therapy because of its direct effect on neutrophils and
inflammatory mediators. This case could thus reveal
an adjuvant treatment option in anemic patients
recalcitrant to standard PG therapies, although
more investigation needs to be done regarding iron’s
effect on various inflammatory mediators.
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